ALK-abello (AKBLF) Price & Analysis

ALK-abello A/S Class B released its earnings results on Nov 12, 2025. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.157 by $0.063.

Is ALK-abello A/S Class B overvalued?

According to Wall Street analysts ALK-abello A/S Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ALK-abello A/S Class B pay dividends?

ALK-abello A/S Class B pays a Annually dividend of $0.25 which represents an annual dividend yield of N/A. See more information on ALK-abello A/S Class B dividends here

What is ALK-abello A/S Class B’s EPS estimate?

ALK-abello A/S Class B’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ALK-abello A/S Class B have?

ALK-abello A/S Class B has 202,567,200 shares outstanding.

What happened to ALK-abello A/S Class B’s price movement after its last earnings report?

ALK-abello A/S Class B reported an EPS of $0.22 in its last earnings report, beating expectations of $0.157. Following the earnings report the stock price went up 3.281%.

Which hedge fund is a major shareholder of ALK-abello A/S Class B?

Currently, no hedge funds are holding shares in AKBLF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ALK-abello A/S Class B

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

ALK-abello (AKBLF) Earnings & Revenues

Historic Earnings Reports

AKBLF Company Deck

AKBLF Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong financial performance, successful product launches, and strategic partnerships, contributing to growth across regions. However, challenges remain in some markets and with traditional product competition, impacting costs.View all AKBLF earnings summaries